Jasper Therapeutics (JSPR) Depreciation & Amortization (CF) (2021 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Depreciation & Amortization (CF) of $334000.0 for Q4 2025, up 22.79% year-over-year from $272000.0 in Q4 2024, and up 67.0% quarter-over-quarter from $200000.0 in Q3 2025.
Jasper Therapeutics (JSPR) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
Jasper Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $334000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 22.79% year-over-year to $334000.0; the TTM figure through Dec 2025 stood at $1.1 million (down 18.16% YoY), while the FY2025 annual figure was $1.1 million, down 21.43% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $334000.0, up from $200000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $500000.0 in Q3 2024, with the low at $22000.0 in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $277000.0 (2023), against an average of $251800.0.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 809.09% in 2022, then plunged 60.0% in 2025.
- Jasper Therapeutics' Depreciation & Amortization (CF) stood at $194000.0 in 2021, then soared by 53.61% to $298000.0 in 2022, then slipped by 7.72% to $275000.0 in 2023, then fell by 1.09% to $272000.0 in 2024, then climbed by 22.79% to $334000.0 in 2025.
- Business Quant data shows JSPR's Depreciation & Amortization (CF) at $334000.0 in Q4 2025, $200000.0 in Q3 2025, and $300000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 334,000.00 |
| Dec 31, 2025 | 334,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 279,000.00 |
| Mar 31, 2025 | 279,000.00 |
| Dec 31, 2024 | 272,000.00 |
| Dec 31, 2024 | 272,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Sep 30, 2023 | 300,000.00 |